DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
tarlatamab - 1 Anish Thomas - 1 “ - 1 Timothy Burns - 1 ” - 1 Amgen - 1 Jay Bradner - 1 Bradner - 1
Top related locs:
U.S Atlanta , Georgia Naperville , Illinois
Top related orgs:
Drug Administration - 2 National Cancer Institute - 1 University of Pittsburgh - 1 of Cancer - 1 CNBC - 1 American Cancer Society - 1

Search resuls for: "tarlatamab"


2 mentions found


☆ F.D.A. Approves Drug for Persistently Deadly Form of Lung Cancer
  + stars: | 2024-05-16 | by ( Gina Kolata | ) www.nytimes.com   time to read: +1 min
The Food and Drug Administration on Thursday approved an innovative new treatment for patients with a form of lung cancer. It is to be used only by patients who have exhausted all other options to treat small cell lung cancer, and have a life expectancy of four to five months. The drug tarlatamab, or Imdelltra, made by the company Amgen, tripled patients’ life expectancy, giving them a median survival of 14 months after they took the drug. After decades with no real advances in treatments for small cell lung cancer, tarlatamab offers the first real hope, said Dr. Anish Thomas, a lung cancer specialist at the federal National Cancer Institute who was not involved in the trial. Dr. Timothy Burns, a lung cancer specialist at the University of Pittsburgh, said that the drug “will be practice-changing.”
Persons: tarlatamab, Anish Thomas, “, Timothy Burns, ” Organizations: Drug Administration, National Cancer Institute, University of Pittsburgh
☆ FDA approves Amgen's treatment for most deadly form of lung cancer
  + stars: | 2024-05-16 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +3 min
In clinical trials, Amgen's drug has been shown to reduce tumor growth and help people with small-cell lung cancer live significantly longer. Of the more than 2.2 million patients who are diagnosed with lung cancer worldwide each year, small-cell lung cancer comprises 15%, or 330,000, of those cases, Amgen said. There are around 35,000 patients with small-cell lung cancer in the U.S., Dr. Jay Bradner, Amgen's chief scientific officer, told CNBC. Small-cell lung cancer usually starts in the airways of the lung and grows rapidly, creating large tumors and spreading throughout the body. Maida Mangiameli, a small-cell lung cancer advocate and patient mentor from Naperville, Illinois, is also a survivor of the devastating disease.
Persons: Amgen, Jay Bradner, Bradner, Lynne Bell, Amgen's, Bell, I'm, Maida, Mangiameli, Amgen's Bradner Organizations: Drug Administration, of Cancer, CNBC, American Cancer Society Locations: U.S, Atlanta , Georgia, Naperville , Illinois
0 next >>
Total: 2